Roche Amplicor PCR tuberculosis test set for U.S. market launch in January.
This article was originally published in The Gray Sheet
Executive Summary
ROCHE AMPLICOR PCR TUBERCULOSIS TEST U.S. LAUNCH slated for the beginning of January at a price of $25 per test, the company says. Roche Diagnostic Systems gained approval for the test on Nov. 26 for detection of mycobacterium tuberculosis (MTB) in patients who have acid fast bacilli (AFB) positive smear results. The assay is the second gene amplification test approved by FDA for the detection of TB.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.